- Home
- CIFR vs GLPG Comparison
CIFR vs GLPG Comparison
Compare CIFR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- GLPG
- Stock Information
- Founded
- CIFR 2021
- GLPG 1999
- Country
- CIFR United States
- GLPG Belgium
- Employees
- CIFR N/A
- GLPG N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- CIFR Finance
- GLPG Health Care
- Exchange
- CIFR Nasdaq
- GLPG Nasdaq
- Market Cap
- CIFR 2.1B
- GLPG 2.0B
- IPO Year
- CIFR N/A
- GLPG 2005
- Fundamental
- Price
- CIFR $6.68
- GLPG $33.29
- Analyst Decision
- CIFR Strong Buy
- GLPG Sell
- Analyst Count
- CIFR 11
- GLPG 4
- Target Price
- CIFR $7.58
- GLPG $25.33
- AVG Volume (30 Days)
- CIFR 49.7M
- GLPG 236.9K
- Earning Date
- CIFR 08-07-2025
- GLPG 07-23-2025
- Dividend Yield
- CIFR N/A
- GLPG N/A
- EPS Growth
- CIFR N/A
- GLPG N/A
- EPS
- CIFR N/A
- GLPG N/A
- Revenue
- CIFR $152,092,000.00
- GLPG $311,493,731.00
- Revenue This Year
- CIFR $87.55
- GLPG $0.78
- Revenue Next Year
- CIFR $68.51
- GLPG N/A
- P/E Ratio
- CIFR N/A
- GLPG N/A
- Revenue Growth
- CIFR N/A
- GLPG 18.32
- 52 Week Low
- CIFR $1.86
- GLPG $22.36
- 52 Week High
- CIFR $7.77
- GLPG $33.43
- Technical
- Relative Strength Index (RSI)
- CIFR 69.33
- GLPG 80.96
- Support Level
- CIFR $5.95
- GLPG $30.75
- Resistance Level
- CIFR $7.10
- GLPG $30.78
- Average True Range (ATR)
- CIFR 0.56
- GLPG 0.63
- MACD
- CIFR 0.03
- GLPG 0.36
- Stochastic Oscillator
- CIFR 77.05
- GLPG 89.97
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.